Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
Reuters
Published Apr 09, 2024 04:32PM ET
Updated Apr 09, 2024 09:06PM ET
(Reuters) -Illumina said on Tuesday Chief Financial Officer Joydeep Goswami will leave the gene sequencing company and be succeeded by former Summit Therapeutics (NASDAQ:SMMT)' executive Ankur Dhingra.
Goswami, who has more than two decades of experience in the life sciences industry, was the CFO since early 2023 and will serve as an adviser till June 30, the company said.
Prior to Summit, Dhingra was the CFO at medical test maker CareDx (NASDAQ:CDNA). He has also spent about 18 years at equipment maker Agilent Technologies (NYSE:A).
Illumina (NASDAQ:ILMN) has also reaffirmed its forecast for the first quarter and full-year 2024.
The company had in February forecast its annual core business revenue to be nearly flat as subdued demand for its genetic testing tools and diagnostics products extends into this year.
Illumina had said in December it would divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from activist investor Carl Icahn.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.